Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular miniaturization and drive vellus-to-terminal hair regeneration by demonstrating that it prolongs anagen, stimulates keratin synthesis, and modulates the stem cell niche Full dataset will be presented during today’s ABS-201 Key Opinion Leader (KOL) seminar VANCOUVER, Wash. and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWI ...

Partnership aims to destigmatize androgenetic alopecia and highlight the need for new therapeutic options that address the root cause of disease Donovan to share his personal journey at Absci’s upcoming Key Opinion Leader seminar VANCOUVER, Wash. and NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced a partnership with U.S. soccer legend Landon Donovan to elevate the ...

Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational trials for androgenetic alopecia (AGA) and Phase 2 for endometriosis KOL seminar scheduled for December 11 to discuss new human ex vivo data, clinical trial design, and market opportunity in AGA VANCOUVER, Wash. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage ...

Core Insights - Acrivon Therapeutics is advancing its clinical pipeline, particularly focusing on ACR-368 for endometrial cancer, with a registrational-intent Phase 2b trial aimed at addressing unmet medical needs in relapsed patients [2][5] - The company is also preparing to disclose initial clinical data for ACR-2316 from its Phase 1 trial, which targets solid tumor types prioritized by its AP3 platform [1][2] - Acrivon's proprietary Generative Phosphoproteomics AP3 platform is enhancing drug discovery by enabling the design of differentiated compounds with desired pathway effects [1][6] Recent Highlights - ACR-368 is a CHK1 and CHK2 inhibitor currently in a multicenter Phase 2b trial for recurrent high-grade endometrial cancer [3][5] - ACR-2316, a WEE1/PKMYT1 inhibitor, has shown promising preclinical data, demonstrating tumor regression in xenograft models [4][5] - The AP3 platform's generative AI model, KaiSR, has been presented at conferences, showcasing its ability to predict pathway activity and support rational drug design [6] Financial Overview - For Q3 2025, Acrivon reported a net loss of $18.2 million, an improvement from a net loss of $22.4 million in Q3 2024 [8] - Research and development expenses decreased to $13.6 million in Q3 2025 from $18.9 million in the same period in 2024, reflecting a focus on endometrial cancer [9] - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $134.4 million, expected to fund operations into Q2 2027 [10] Upcoming Milestones - Acrivon plans to provide updates on the registrational-intent trial for ACR-368 and report initial clinical data for ACR-2316 in the second half of 2025 [13][14] - The company is also advancing a new potential first-in-class cell cycle drug discovery program towards candidate nomination in 2025 [13]

Core Insights - Absci, a clinical-stage biotech company, is set to report its third quarter 2025 business updates and financial results on November 12, 2025, after market close [1] - A conference call will follow the report, starting at 4:30 p.m. Eastern Time, to discuss business developments and outlook [2] Company Overview - Absci is focused on drug discovery using generative design to create biologics more efficiently [3] - The company utilizes its Integrated Drug Creation™ platform, which combines AI models with a synthetic biology data engine for rapid therapeutic design [3] - Absci's pipeline includes ABS-101, aimed at treating inflammatory bowel disease, and ABS-201, a novel treatment for androgenetic alopecia [3] - The company operates from Vancouver, WA, with additional facilities in New York City and Switzerland [3]

Core Insights - Acrivon Therapeutics is advancing its precision medicine development through its proprietary Generative Phosphoproteomics AP3 platform, which enables the assessment of drug effects on intracellular protein signaling networks for optimal drug design and precision medicine [1][4][5] - The company has reported favorable preclinical data for its lead asset ACR-2316, a novel WEE1/PKMYT1 inhibitor, demonstrating superior pathway effects compared to benchmark inhibitors [1][7] - Initial clinical data for ACR-2316 is expected to be reported later this year, with confirmed partial responses observed during the dose escalation phase of the trial [1][2][7] Presentation Details - Acrivon will present three posters at the AACR-NCI-EORTC International Conference, showcasing the AP3 platform and the preclinical activity of ACR-2316 [2][3] - The posters will cover topics such as the global pharmacodynamic effects of ACR-2316, the generative AI ensemble model (KaiSR), and the design of ACR-2316 for optimal pro-apoptotic pathway effects [3] Company Overview - Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines using its AP3 platform [4][5] - The company is also advancing ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2b trial for endometrial cancer, with Fast Track designation from the FDA [6][7] - Acrivon is leveraging its platform for developing additional pipeline programs, including ACR-2316, which has shown strong preclinical activity and is currently in a Phase 1 trial [7]

Core Insights - Absci is hosting a virtual seminar on December 11, 2025, to discuss its ABS-201 program for androgenetic alopecia, featuring leading KOLs in dermatology and hair loss [1][2] - The Phase 1/2a trial for ABS-201 is now expected to begin in early December 2025, ahead of previous guidance for early 2026, with interim efficacy results anticipated in the second half of 2026 [2][5] Company Overview - Absci is a clinical-stage biotech company focused on advancing therapeutics using generative AI, with a platform that integrates AI models and synthetic biology to create innovative biologics [6] - The company is developing ABS-201, a novel therapeutic targeting prolactin receptors to stimulate hair follicle regeneration, showing superior hair regrowth compared to minoxidil in preclinical studies [5][6] Market Context - Androgenetic alopecia affects approximately 80 million Americans, with current FDA-approved treatments like minoxidil and finasteride having limited efficacy and notable side effects [4] - ABS-201 aims to redefine treatment possibilities for androgenetic alopecia, addressing a significant unmet need in the market [5][6] Event Details - The webinar will feature presentations on the ABS-201 program's latest developments, followed by an interactive Q&A session, concluding around 12:00 p.m. ET [3] - Key opinion leaders presenting include Dr. David J. Goldberg, Dr. Ralf Paus, and Dr. Rodney Sinclair, among others [7]

Core Viewpoint - Absci Corp. is positioned in the high-risk, high-reward biotech sector, leveraging AI and machine learning for drug discovery, with a market cap of approximately $600 million [1][2]. Group 1: Company Overview - Absci operates at the intersection of AI and biotechnology, utilizing advanced technologies to discover and develop new therapeutics, which positions it as a leader in a growing trend within the biotech industry [2]. - The company employs generative AI to model and design components for new therapeutics, potentially shortening the typical R&D timeline [3]. - Absci has multiple drug candidates in clinical trials, including ABS-101 for IBD and ABS-201 for androgenic alopecia, with its Integrated Drug Creation platform being crucial for development [3]. Group 2: Partnerships and Collaborations - Absci has established significant partnerships with major biotech and pharmaceutical companies, including a nearly four-year partnership with Merck, potentially worth up to $610 million [4]. - The company also collaborates with medical dermatology firm Almirall and other entities, enhancing its position in the market [4]. Group 3: Market Potential and Financials - The AI drug discovery market is projected to grow at a CAGR of nearly 30% from 2024 to 2030, reaching over $20 billion, indicating a substantial growth opportunity for Absci [6]. - Absci raised approximately $64 million in July 2025, increasing its cash reserves to over $117 million, providing financial stability into 2028 [7]. Group 4: Risks and Challenges - Absci faces execution and clinical risks, as it currently has no commercialized therapies and relies heavily on research collaborations for revenue [8]. - The company must overcome the common challenges faced by early-stage biotech firms, including transitioning from lab success to clinical success and commercialization [9]. - Increased competition from other biotech firms and legacy pharmaceutical companies expanding their AI capabilities adds uncertainty to Absci's growth prospects [9]. Group 5: Analyst Sentiment - Analysts are generally optimistic about Absci, with six out of seven assigning a Buy rating and forecasting an upside potential of over 110% [10].

Core Insights - Absci is advancing ABS-201, an AI-designed therapeutic antibody for treating androgenetic alopecia, with guidance from renowned dermatologists [1][4][5] - Androgenetic alopecia affects approximately 80 million Americans, with current FDA-approved treatments showing limited efficacy [2] - ABS-201 targets prolactin receptors to stimulate hair follicle regeneration, demonstrating superior hair regrowth compared to minoxidil in preclinical studies [3] Company Overview - Absci is a clinical-stage biotech company utilizing generative AI for drug discovery, aiming to create better biologics faster [7][8] - The company’s Integrated Drug Creation™ platform combines AI models with synthetic biology to innovate therapeutics [7] - Absci is headquartered in Vancouver, WA, with additional facilities in New York City and Switzerland [8] Scientific Advisory Board - Dr. Rodney Sinclair and Dr. David Goldberg have joined the ABS-201 Scientific Advisory Board, bringing extensive expertise in dermatology and hair loss [1][4][6] - Dr. Sinclair has over three decades of experience and has authored over 1000 publications in dermatology [4][5] - Dr. Goldberg has nearly four decades of clinical experience and has conducted pivotal research studies in hair loss, including original Minoxidil trials [5][6] Clinical Development - Phase 1/2a clinical trials for ABS-201 are set to begin in early 2026, with initial proof-of-concept data expected in the second half of 2026 [3] - The novel mechanism of action of ABS-201 offers potential for a durable therapy, addressing the limitations of current treatments that require continuous usage [5][6]

Core Insights - Almirall and Absci Corporation are expanding their AI Drug Discovery collaboration to include a second target for dermatological indications, building on the success of their initial collaboration [1][2][4] - The collaboration leverages Absci's Integrated Drug Creation™ platform and Almirall's dermatology expertise to accelerate the development of innovative therapeutics for chronic skin diseases [2][3] - Absci is eligible for up to approximately $650 million in payments across both programs, in addition to royalties on potential product sales [3] Company Overview - Almirall is a global biopharmaceutical company focused on medical dermatology, founded in 1944 and headquartered in Barcelona, with total revenue of €990 million in 2024 and over 2000 employees globally [5][6] - Absci is a clinical-stage biopharmaceutical company that utilizes generative AI for drug discovery, aiming to create better biologics faster [8][9] Collaboration Details - The initial collaboration, announced in November 2023, successfully delivered AI-designed functional antibody leads against a difficult-to-drug target [2][4] - Absci's generative AI platform is combined with wet lab capabilities to design and validate therapeutic candidates, while Almirall leads the preclinical and clinical development [3][4] - The collaboration aims to accelerate innovation in dermatology by utilizing generative AI for new therapeutic approaches [4]